Leukemia researcher wins city’s highest award
Print Edition
A RESEARCHER who made a breakthrough in the study of leukemia was honored by the city government with the highest award at the Shanghai Science and Technology Awards yesterday.
Chen Saijuan, from Ruijin Hospital, was the leader of a team which decoded leukemia mechanism through genetic screening technology and discovered a series of new molecular targets for leukemia diagnosis and treatment, including a new therapy for acute promyelocytic leukemia (APL), which can now be cured.
Chen and her colleagues began to treat APL with a combination of traditional Chinese medicine — arsenic and all-trans retinoic acid — the acid form of vitamin A and proved the effects through molecular mechanism.
“The therapy for APL is named Shanghai Scheme and has been widely recognized in the world and used in many international blood centers and hospitals,” said Chen Saijuan, whose team has focused on TCM treatment of leukemia with the aid of modern technology.
“An Italian patient sent me a letter of gratitude after successfully trying out the Shanghai Scheme. It is such a great joy for me and my team,” Chen said.
A total of 287 persons and projects won awards yesterday. Mohamad Sawan from Canada, Chen Hongyu from the United States and Gilles Mailhot from France were honored for their contribution in international technology cooperation.
The three industries — biology and medicine, information technology, energy and environment — were among the top winners.
They covered almost 60 percent of the awards. Biology and medicine won as many as 29 percent awards, according to officials from Shanghai Science and Technology Commission.
- About Us
- |
- Terms of Use
- |
-
RSS - |
- Privacy Policy
- |
- Contact Us
- |
- Shanghai Call Center: 962288
- |
- Tip-off hotline: 52920043
- 沪ICP证：沪ICP备05050403号-1
- |
- 互联网新闻信息服务许可证：31120180004
- |
- 网络视听许可证：0909346
- |
- 广播电视节目制作许可证：沪字第354号
- |
- 增值电信业务经营许可证：沪B2-20120012
Copyright © 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.
